I guess if institutional investors know they can get in cheaply, there is no way they will buy from retail which has so painfully hung on all this time. The only escape from the 25% dilution is to participate in the SPP. I'm not too sure what to do here. Well financed (now) and significant clinical trials to date.
News: OPT Opthea Ltd Says Offer Price For $90 Million Placement Is A$1.15 Per New Share, page-2
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.5¢ |
Change
-0.035(6.73%) |
Mkt cap ! $321.4M | |||
| Open | High | Low | Value | Volume |
| 50.5¢ | 50.5¢ | 47.5¢ | $314.0K | 642.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3270 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.5¢ | 9056 | 2 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
48.5¢ |
Change
-0.035 ( 6.73 %) |
||||
| Open | High | Low | Volume | ||
| 49.0¢ | 50.0¢ | 47.5¢ | 78801 | ||
| Last updated 15.59pm 06/06/2024 ? | |||||
| OPT (ASX) Chart |